Cyclin-dependent kinases (CDKs) (CDKs)

Cyclin-dependent kinases (CDKs) are a family of serine/threonine protein kinases that regulate crucial aspects of the cell cycle and gene transcription. While all require binding to a regulatory cyclin partner for activity, individual CDKs play distinct roles: - CDK4 partners with D-type cyclins (D1, D2, D3) to drive early G1 progression and phosphorylation of retinoblastoma protein (Rb), promoting S-phase entry[1][5][9]. - CDK1 is essential for cell cycle progression, controlling G2/M transition by partnering with cyclin A and cyclin B, and is the only CDK absolutely required for mitosis and cell division in mammals[2][5][6][10]. - CDK9 associates with cyclin T (as P-TEFb complex) to regulate transcriptional elongation via phosphorylation of the C-terminal domain of RNA polymerase II, playing a key role in gene expression and response to stress[3][4][8]. These kinases are important oncogenic drivers and validated therapeutic targets for diverse malignancies, with several selective inhibitors now approved for clinical use (notably CDK4/6 inhibitors for HR-positive breast cancer)[5][4][9]. The listing of three different proteins as a single target is technically incorrect for data structuring; each should have its own canonical entry with specific attributes as described above. If you need detailed, structured information for each individual kinase (CDK4, CDK1, CDK9), let me know which one you would like to start with.

ATP-competitive inhibition of kinase activity Blockade of substrate phosphorylation, halting cell cycle progression or transcription